x
uploads/ergot.jpg

ergot n.1.麥角,麥角堿,麥角菌。2.【農業】(植物的)麥角...

ergotamine

Results clinically important regurgitation ( moderate to severe , grade 3 to 4 ) in any valve was found with significantly greater frequency in patients taking pergolide ( 23 . 4 % ) or cabergoline ( 28 . 6 % ) but not in patients taking non ? ergot - derived dopamine agonists ( 0 % ) , as compared with control subjects ( 5 . 6 % ) 結果:與對照組相比( 5 . 6 % ) ,服用培高利特( 23 . 4 % )或者卡麥角林的患者( 28 . 6 % ) ,臨床上發生重要的任何瓣膜的返流(中到重度, 3級到4級)的頻率顯著升高,而服用非麥角?生的多巴胺受體激動劑的患者( 0 % )瓣膜返流的發生率卻未增加。

Methods we performed an echocardiographic prevalence study in 155 patients taking dopamine agonists for parkinson ' s disease ( pergolide , 64 patients ; cabergoline , 49 ; and non ? ergot - derived dopamine agonists , 42 ) and 90 control subjects 方法:我們用超聲心動圖對155例正在服用多巴胺受體激動劑( 64例服用培高利特, 49例服用卡麥角林, 42例服用非麥角?生的多巴胺受體激動劑)治療帕金森病的患者和90例對照組進行了一項流行調查。

Background case reports and echocardiographic studies suggest that the ergot - derived dopamine agonists pergolide and cabergoline , used in the treatment of parkinson ' s disease and the restless legs syndrome , may increase the risk of cardiac - valve regurgitation 背景:病例報告和超聲心動圖研究提示,用于治療帕金森病和不寧腿綜合征的藥物?麥角?生物,多巴胺受體激動劑培高利特和卡麥角林,可能增加發生心臟瓣膜返流的風險。

Conclusions the frequency of clinically important valve regurgitation was significantly increased in patients taking pergolide or cabergoline , but not in patients taking non ? ergot - derived dopamine agonists , as compared with control subjects 結論:與對照組相比,服用培高利特或者卡麥角林的患者臨床上發生重要瓣膜返流的頻率顯著增加,但服用非麥角?生的多巴胺受體激動劑的患者瓣膜返流的發生率卻未增加。

Patients treated with ergot derivatives who had grade 3 to 4 regurgitation of any valve had received a significantly higher mean cumulative dose of pergolide or cabergoline than had patients with lower grades 在服用麥角?生物進行治療的患者中,發生任何瓣膜3到4級返流的患者服用培高利特或卡麥角林的平均累積劑量顯著高于瓣膜返流級別較低的患者。

The mean mitral tenting area was significantly greater in ergot - treated patients and showed a linear relationship with the severity of mitral regurgitation 服用麥角?生物的患者其二尖瓣幕狀區的均值顯著增加,且和二尖瓣返流的嚴重程度成線性關系。

These findings should be considered in evaluating the risk ? benefit ratio of treatment with ergot derivatives 在評估使用麥角?生物進行治療的風險-效益比率時應考慮到這一點。

Ergot a fungal disease of many cereals 麥角菌:是許多谷類農作物感染的一種真菌病。